Drug-drug interactions that interfere with statin metabolism

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Introduction: Lipid-lowering drugs, especially hydroxymethylglutaryl-CoA reductase inhibitors (statins), are widely used in the treatment and prevention of atherosclerotic diseases. The benefits of statins are well documented. However, myotoxic side effects, which can sometimes be severe, including myopathy or rhabdomyolysis, have been associated with the use of statins. In some cases, this toxicity is associated with pharmacokinetic alterations. Potent inhibitors of CYP 3A4 significantly increase plasma concentrations of the active forms of simvastatin, lovastatin and atorvastatin. Fluvastatin is metabolized by CYP2C9, while pravastatin, rosuvastatin and pitavastatin are not susceptible to inhibition by any CYP.Areas covered: This review discusses the pharmacokinetic aspects of the drug-drug interaction with statins and genetic polymorphisms in CYPs, which are involved in the metabolism of statins, and highlights the importance of establishing a system utilizing electronic medical information practically to avoid adverse drug reactions.Expert opinion: An understanding of the mechanisms underlying statin interactions will help to minimize drug interactions and develop statins that are less prone to adverse interactions. Quantitatively analyzed information for the low-density lipoprotein cholesterol lowering effects of statin based on electronic medical records may be useful for avoiding the adverse effect of statins.

Original languageEnglish
Pages (from-to)1435-1447
Number of pages13
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume11
Issue number9
DOIs
Publication statusPublished - Sep 2 2015

Fingerprint

Drug interactions
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Drug Interactions
Metabolism
Pharmaceutical Preparations
Electronic medical equipment
Pharmacokinetics
fluvastatin
Medical Electronics
Pravastatin
Lovastatin
Rhabdomyolysis
Simvastatin
Electronic Health Records
Expert Testimony
Muscular Diseases
Genetic Polymorphisms
Drug-Related Side Effects and Adverse Reactions
Polymorphism
LDL Cholesterol

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology

Cite this

Drug-drug interactions that interfere with statin metabolism. / Hirota, Takeshi; Ieiri, Ichiro.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 11, No. 9, 02.09.2015, p. 1435-1447.

Research output: Contribution to journalReview article

@article{f1b657a77aa045338a2c9876e03943f0,
title = "Drug-drug interactions that interfere with statin metabolism",
abstract = "Introduction: Lipid-lowering drugs, especially hydroxymethylglutaryl-CoA reductase inhibitors (statins), are widely used in the treatment and prevention of atherosclerotic diseases. The benefits of statins are well documented. However, myotoxic side effects, which can sometimes be severe, including myopathy or rhabdomyolysis, have been associated with the use of statins. In some cases, this toxicity is associated with pharmacokinetic alterations. Potent inhibitors of CYP 3A4 significantly increase plasma concentrations of the active forms of simvastatin, lovastatin and atorvastatin. Fluvastatin is metabolized by CYP2C9, while pravastatin, rosuvastatin and pitavastatin are not susceptible to inhibition by any CYP.Areas covered: This review discusses the pharmacokinetic aspects of the drug-drug interaction with statins and genetic polymorphisms in CYPs, which are involved in the metabolism of statins, and highlights the importance of establishing a system utilizing electronic medical information practically to avoid adverse drug reactions.Expert opinion: An understanding of the mechanisms underlying statin interactions will help to minimize drug interactions and develop statins that are less prone to adverse interactions. Quantitatively analyzed information for the low-density lipoprotein cholesterol lowering effects of statin based on electronic medical records may be useful for avoiding the adverse effect of statins.",
author = "Takeshi Hirota and Ichiro Ieiri",
year = "2015",
month = "9",
day = "2",
doi = "10.1517/17425255.2015.1056149",
language = "English",
volume = "11",
pages = "1435--1447",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Drug-drug interactions that interfere with statin metabolism

AU - Hirota, Takeshi

AU - Ieiri, Ichiro

PY - 2015/9/2

Y1 - 2015/9/2

N2 - Introduction: Lipid-lowering drugs, especially hydroxymethylglutaryl-CoA reductase inhibitors (statins), are widely used in the treatment and prevention of atherosclerotic diseases. The benefits of statins are well documented. However, myotoxic side effects, which can sometimes be severe, including myopathy or rhabdomyolysis, have been associated with the use of statins. In some cases, this toxicity is associated with pharmacokinetic alterations. Potent inhibitors of CYP 3A4 significantly increase plasma concentrations of the active forms of simvastatin, lovastatin and atorvastatin. Fluvastatin is metabolized by CYP2C9, while pravastatin, rosuvastatin and pitavastatin are not susceptible to inhibition by any CYP.Areas covered: This review discusses the pharmacokinetic aspects of the drug-drug interaction with statins and genetic polymorphisms in CYPs, which are involved in the metabolism of statins, and highlights the importance of establishing a system utilizing electronic medical information practically to avoid adverse drug reactions.Expert opinion: An understanding of the mechanisms underlying statin interactions will help to minimize drug interactions and develop statins that are less prone to adverse interactions. Quantitatively analyzed information for the low-density lipoprotein cholesterol lowering effects of statin based on electronic medical records may be useful for avoiding the adverse effect of statins.

AB - Introduction: Lipid-lowering drugs, especially hydroxymethylglutaryl-CoA reductase inhibitors (statins), are widely used in the treatment and prevention of atherosclerotic diseases. The benefits of statins are well documented. However, myotoxic side effects, which can sometimes be severe, including myopathy or rhabdomyolysis, have been associated with the use of statins. In some cases, this toxicity is associated with pharmacokinetic alterations. Potent inhibitors of CYP 3A4 significantly increase plasma concentrations of the active forms of simvastatin, lovastatin and atorvastatin. Fluvastatin is metabolized by CYP2C9, while pravastatin, rosuvastatin and pitavastatin are not susceptible to inhibition by any CYP.Areas covered: This review discusses the pharmacokinetic aspects of the drug-drug interaction with statins and genetic polymorphisms in CYPs, which are involved in the metabolism of statins, and highlights the importance of establishing a system utilizing electronic medical information practically to avoid adverse drug reactions.Expert opinion: An understanding of the mechanisms underlying statin interactions will help to minimize drug interactions and develop statins that are less prone to adverse interactions. Quantitatively analyzed information for the low-density lipoprotein cholesterol lowering effects of statin based on electronic medical records may be useful for avoiding the adverse effect of statins.

UR - http://www.scopus.com/inward/record.url?scp=84939802008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939802008&partnerID=8YFLogxK

U2 - 10.1517/17425255.2015.1056149

DO - 10.1517/17425255.2015.1056149

M3 - Review article

C2 - 26058399

AN - SCOPUS:84939802008

VL - 11

SP - 1435

EP - 1447

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 9

ER -